SCHEMBL448147

SCHEMBL448147

Brc1cnco1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8709145 0.65
SCHEMBL47206 0.65
SCHEMBL2008205 0.62
SCHEMBL682505 0.59
SCHEMBL10768177 0.59 PKM (0.78)
SCHEMBL272744 0.57
SCHEMBL7442697 0.57
SCHEMBL18483391 0.57
SCHEMBL193967 0.57
SCHEMBL14042394 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010938-A Pyrido [1, 2-a ] pyrimidine mesoionic derivative containing five-membered heterocyclic structure, and preparation and application thereof 贵州大学 2026-05-12 CN disclosed
EP-4688789-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 EP disclosed
US-20250129070-A1 BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS KOLM THERAPEUTICS INC. 2025-04-24 US disclosed
WO-2025081082-A1 BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS KOLM THERAPEUTICS INC. (US) 2025-04-17 WO disclosed
WO-2025036241-A1 COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING RIBOPEUTIC INC. (CN) 2025-02-20 WO disclosed
WO-2024211663-A9 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-01-30 WO disclosed
WO-2024211663-A1 CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS Revolution Medicines, Inc. (US) 2024-10-10 WO disclosed
CN-116731038-A Nitrogen-containing heterocyclic compound, and preparation method and application thereof 苏州亚盛药业有限公司 2023-09-12 CN disclosed
WO-2021130515-A1 STRUCTURALLY SIMPLIFIED DIAZONAMIDE ANALOGS AS ANTIMITOTIC AGENTS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2021-07-01 WO disclosed
CN-112409378-A Tricyclic PI3K inhibitor compounds and methods of use thereof 豪夫迈·罗氏有限公司 2021-02-26 CN disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed
US-5958973-A Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors GILEAD SCIENCES, INC. (US) 1999-09-28 US disclosed
US-5512596-A Aromatic compounds GILEAD SCIENCES, INC. (US) 1996-04-30 US disclosed
CN-1082043-A Be applicable to that the preparation antithrombotic forms and the compound 7-oxabicyclo heptyl of vasospasm replaces De oxazole amide prostaglandin analog intermediates preparation SQUIBB & SONS INC (US) 1994-02-16 CN disclosed
US-5283363-A Reacting a halogeno(hetero)aryl compound with aminoalkynyl compounds; catalysts; hydrogenation BAYER AKTIENGESELLSCHAFT (DE) 1994-02-01 US disclosed
US-5281716-A Enzyme inhibitors for anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 1994-01-25 US disclosed
EP-0575069-A1 Method for preparing 7-oxabicycloheptyl substituted oxazole amide prostaglandin analog intermediates useful in the preparation of antithrombotic and anti-vasospastic compounds E.R. Squibb &amp; Sons, Inc. (US) 1993-12-22 EP disclosed
EP-0497133-A1 Process for the preparation of (hetero)arylalk(en/in)-ylamines and (hetero)arylalkinylamines per se BAYER AG (DE) 1992-08-05 EP disclosed
US-4180670-A Amino pyridine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1979-12-25 US disclosed